查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179914

2022-2029 年全球結合疫苗市場

Global Conjugate Vaccine Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內（2022 年至 2029 年），結合疫苗的全球市場規模預計將以 9.5% 的複合年增長率增長。

結合疫苗是一種亞單位疫苗，以強抗原和弱抗原結合為載體，增強免疫系統對弱抗原的反應。 有針對傳染病的結合疫苗。 一些細菌和病毒具有多醣外殼以逃避免疫系統。 如果免疫系統不成熟，就可以識別這些細菌，因為這些疫苗接種會引發免疫力和將生物體與獨特的多醣外殼結合的反應。 結合疫苗的例子包括腦膜炎球菌疫苗、b 型流感嗜血桿菌 (Hib) 疫苗和預防腦膜炎的肺炎球菌疫苗。

市場動態

擴大腦膜炎球菌結合疫苗的許可、越來越多的主要參與者開發和引入肺炎球菌和腦膜炎球菌疫苗，以及疫苗接種計劃意識的提高預計將在預測期內推動市場增長。已成為推動因素

FDA 批准結合疫苗的增加預計將推動市場的增長。

2022 年 12 月 28 日，輝瑞公司宣布美國食品藥品監督管理局 (FDA) 已向該公司的研究性五價腦膜炎球菌候選疫苗 (MenABCWY) 提交生物製品許可申請 (BLA) 以供審查。宣布其已被接受了。 輝瑞公司提交 MenABCWY 以預防腦膜炎球菌病，這是由於 10-25 歲人群中最常見的血清群所致。 此外，GSK plc 將於 2022 年 10 月 17 日推出適用於 10 至 55 歲人群的 Menbeo，以預防由腦膜炎奈瑟球菌血清群 A、C、Y 和 W 引起的侵襲性腦膜炎球菌病。宣布 FDA 已經批准了一種新的製造工藝腦膜炎球菌（A、C、Y 和 W-135 組）低聚醣白喉 CRM197 結合疫苗。 Membeo One 小瓶製劑現在是一種即用型單劑量小瓶製劑，提高了醫療保健專業人員的便利性。 Menbeo One 小瓶展示最初將面向美國聯邦政府客戶提供，預計將於 2023 年年中更廣泛地提供。 因此，上述因素有望在預測期內推動市場。

結合疫苗沒有副作用預計會阻礙市場增長。

結合疫苗副作用小，即使發生也很輕微，具有恢復快的特點。 在大約 10% 的結合疫苗接種者中觀察到常見的副作用，例如硬化、發紅、注射部位腫脹、不適、中度發燒和超敏反應。 還觀察到其他影響，但很少見且很快消散。 與所有藥物和疫苗一樣，對疫苗或其成分之一產生過敏反應的風險很小。 大多數過敏反應是輕微的（不超過皮疹），但在極少數情況下會發生過敏性休克。 因此，預計上述因素將在預測期內阻礙市場。

COVID-19 影響分析

冠狀病毒大流行對結合疫苗市場產生了一定影響。 MenC 疫苗在 11 個州以及巴西北部和南部接種。 MenC 疫苗覆蓋率下降是 COVID-19 大流行期間遇到的挑戰之一，這可能導致巴西腦膜炎球菌感染率上升。 例如，研究期間共接種了14,832,054例丙型腦膜炎球菌結合疫苗，66.30%是2019年3月至2020年2月，3%是2020年。33.70%是5月至12月實施的。 根據檢測到的統計顯著步驟（分別為 26.98%、41.47%），COVID-19 大流行對北部和南部地區以及巴西 11 個州的 MenC 疫苗接種產生了負面影響。

另一方面，由於美國食品和藥物管理局 (FDA) 在大流行期間增加了疫苗批准，全球結合疫苗市場擴大。 例如，, 輝瑞公司和 BioNTech S.E. 於 2021 年 8 月宣布美國食品和藥物管理局 (FDA) 宣布 COMIRNATY（COVID-19 疫苗，mRNA）宣布已授予其生物製品許可證應用程序 (BLA)。 大量的申請數據，包括第二劑後 6 個月的療效和安全性數據，作為批准的依據。 由於上述背景，該市場受到影響，未來有望進一步擴大。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第4章市場動態

  • 市場影響因素
    • 司機
      • 由於 FDA 越來越多地批准結合疫苗，預計市場會增長。
    • 約束因素
      • 結合疫苗沒有副作用，預計會阻礙市場增長。
    • 機會
    • 影響分析

第5章行業分析

  • 搬運工的五種力量
  • 供應鏈
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 單價結合疫苗
  • 多價結合疫苗

第8章疾病與適應症

  • 肺炎球菌
  • 流感
  • 腦膜炎球菌
  • 其他

第9章病原體類型

  • 細菌
  • 病毒式傳播

第 10 章按患者類型分類

  • 兒科
  • 成人

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第13章公司簡介

  • 葛蘭素史克公司。
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Merck & Co. Inc.
  • Fablife
  • SutroVax Inc.
  • Sanofi Pasteur SA.
  • Pfizer
  • Sinovac Biotech Ltd.
  • IDT Biologics GmbH
  • GreenSignal Bio Pharma Limited
  • Taj Pharmaceuticals Limited
  • Bavarian Nordic

第14章 全球結合疫苗市場-DataM

簡介目錄
Product Code: DMPH1515

Market Overview

The global conjugate vaccine market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 9.5% during the forecast period (2022-2029).

A conjugate vaccination is a subunit vaccine that uses a strong antigen as a carrier to combine a weak antigen, increasing the immune system's response to the weak antigen. Conjugate vaccines for infectious diseases are available. Some bacteria and viruses have polysaccharide coats that allow them to evade the immune system. An immature immune system can recognize these bacteria when conjugate vaccines are used because these vaccinations connect the unique polysaccharide coats to an organism by eliciting immunity and reaction. Meningococcal vaccinations to prevent meningitis, the Haemophilus influenzae type B (Hib) vaccine, and the pneumococcal vaccine are all examples of conjugate vaccines.

Market Dynamics

Growing approval for the meningococcal conjugate vaccine, increasing key players for developing and introducing vaccines for pneumococcal and meningococcal vaccines, and rising awareness about vaccination programs are the factors to drive the market in the forecast period.

The increasing FDA approvals for conjugate vaccines are expected to drive market growth.

On December 28, 2022, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine candidate (MenABCWY). Pfizer submitted MenABCWY to prevent meningococcal disease caused by the most common serogroups in individuals 10 through 25 years of age. Additionally, on October 17, 2022, GSK plc announced that the FDA had approved a new formulation of Menveo [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diptheria CRM197 Conjugate Vaccine] for individuals aged 10 to 55 years to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. The Menveo one-vial presentation is now available in a ready-to-use single vial, making it more convenient for healthcare providers. The Menveo one-vial presentation will initially be available to federal customers in the United States, with broader availability expected in mid-2023. Thus, from the above factors, the market is expected to drive in the forecast period.

Fewer side effects of the conjugate vaccine are expected to hamper the market growth.

The conjugate vaccines have had few side effects; when they have occurred, they have been mild and resolved quickly. About 10% of persons getting conjugate vaccines have common side effects such as hardening, reddening, swelling where the injection is given, malaise, moderate fever, and irritability. Other effects have been observed, but they are uncommon and disappear quickly. There is a small risk of an allergic reaction to the vaccine or one of its components, as with all medicines and vaccines. Most allergic reactions are mild (a skin rash and nothing more), but in extremely rare cases, anaphylactic shock can occur. Hence, from the above factors, the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis

The coronavirus pandemic has moderately impacted the conjugate vaccine market. MenC vaccine doses were given out in 11 Brazilian states and Northern and Southern Brazil. Reduced MenC vaccine coverage is one of the difficulties encountered during the COVID-19 pandemic, and as a result, it may raise meningococcal infection rates in Brazil. For instance, 14,832,054 doses of the meningococcal C conjugate vaccination were delivered overall during the study period, with 66.30% occurring between March 2019 and February 2020 and 33.70% between March and December 2020. The COVID-19 pandemic had a negative effect on the number of MenC vaccine doses delivered in the North and South regions (26,98% and 41.47%, respectively), as well as in the eleven Brazilian States, according to statistically significant steps that were detected.

In contrast, the global market for conjugate vaccines has grown due to the U.S. FDA's (Food and Drug Administration) expanding vaccine approvals during the pandemic. For instance, Pfizer Inc. and BioNTech S.E. announced in August 2021 that the U.S. Food and Drug Administration (FDA) had approved the Biologics License Application (BLA) for COMIRNATY (COVID-19 Vaccine, mRNA), which is intended to prevent COVID-19 in people 16 years of age and older. A thorough submission package, which included six-month efficacy and safety data after the second dose, formed the foundation for the approval. Thus, from the above factors, the market got affected and is expected to boost in the forecast period.

Segment Analysis

Multivalent Conjugate Vaccine segment is expected to hold the largest market share in conjugate vaccine market

The multivalent conjugate vaccine segment accounted for the largest market share in 2021. The multivalent immunogenic conjugates are synthesized using hydrazide chemistry to conjugate mixtures of more than one polysaccharide (at the desired ratio) to at least one carrier protein. Moreover, multivalent conjugate vaccines are cost-effective, improve manufacturing efficiency, streamline the preparation of combined conjugate vaccines, and can also be used to conjugate mixtures of other reagents (peptides, therapeutic agents) to carrier proteins to create therapeutics and reagents compared to monovalent conjugate vaccines. Therefore, it has increased the demand for multivalent conjugate vaccines. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global conjugate Vaccine market

North America region accounted for the largest market share in 2021. The rise in the prevalence of the infectious disease, the increase in the initiatives by the government, the increasing FDA approvals for the conjugate vaccine, and the rising demand for meningococcal, pneumococcal vaccines and other conjugate vaccines are the factors to drive the market in the forecast period. For instance, On April 24, 2020, the FDA approved a Biologics License Application for the MenQuadfi Meningococcal Conjugate Vaccine to prevent invasive meningococcal disease in people two years older. MenQuadfi is a quadrivalent meningococcal vaccine that uses tetanus toxoid as a protein carrier in the United States. It is available in a ready-to-use liquid formulation, eliminating the need for vaccine reconstitution for healthcare providers. Additionally, On August 31, 2022, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of the vaccines for use as single booster dose at least two months following primary or booster vaccination. Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the conjugate vaccine market are GlaxoSmithKline plc, Merck & Co. Inc., Fablife, SutroVax Inc., Sanofi Pasteur SA., Pfizer, Sinovac Biotech Ltd., IDT Biologics GmbH, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited and Bavarian Nordic.

On June 08, 2021, Pfizer Inc. announced that the FDA approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) to prevent invasive disease and pneumonia caused by the vaccine's 20 Streptococcus pneumoniae (pneumococcus) serotypes in adults 18 years and older.

GlaxoSmithKline plc:

Overview:

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat acute and chronic diseases. The Vaccines business provides vaccines for people of all ages, from babies and adolescents to adults and older people. It has a portfolio of medicines for respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty Products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Product Portfolio:

Infanrix hexa: Infanrix hexa is a vaccine used to protect babies and toddlers against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio) and diseases such as bacterial meningitis caused by the bacterium Haemophilus influenzae type b (Hib).

The global conjugate vaccine market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing FDA approvals for conjugate vaccines are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Fewer side effects of the conjugate vaccine are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Monovalent Conjugate Vaccines*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Multivalent Conjugate Vaccine

8. By Disease Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 8.1.2. Market Attractiveness Index, By Disease Indication
  • 8.2. Pneumococcal*
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Influenza
  • 8.4. Meningococcal
  • 8.5. Others

9. By Pathogen Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 9.1.2. Market Attractiveness Index, By Pathogen Type
  • 9.2. Bacterial*
      • 9.2.1.1. Introduction
      • 9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Viral

10. By Patient Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.1.2. Market Attractiveness Index, By Patient Type
  • 10.2. Pediatric*
      • 10.2.1.1. Introduction
      • 10.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Adults

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. GlaxoSmithKline plc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Merck & Co. Inc.
  • 13.3. Fablife
  • 13.4. SutroVax Inc.
  • 13.5. Sanofi Pasteur SA.
  • 13.6. Pfizer
  • 13.7. Sinovac Biotech Ltd.
  • 13.8. IDT Biologics GmbH
  • 13.9. GreenSignal Bio Pharma Limited
  • 13.10. Taj Pharmaceuticals Limited
  • 13.11. Bavarian Nordic

LIST NOT EXHAUSTIVE

14. Global Conjugate Vaccine Market- DataM

  • 14.1. Appendix
  • 14.2. About Us
  • 14.3. Contact Us